ライフサイエンスコーパス: daratumumab

1 and ixazomib, panobinostat, elotuzumab, and daratumumab).

2 es showed a specific tumoral accumulation of Daratumumab.

3 treated with 185 kBq or 277.5 kBq of (212)Pb-Daratumumab.

4 eactivity, and specificity of [(89)Zr]Zr-DFO-daratumumab.

5 achieved with a 200-fold excess of unlabeled daratumumab.

6 to target one another after the addition of daratumumab.

7 CD38, the target of the therapeutic antibody daratumumab.

8 matological cancers, including rituximab and daratumumab.

9 counted life-years compared with second-line daratumumab.

10 ontrol in 2 therapeutic mouse models, unlike daratumumab.

11 MM (r/r MM) displaying lower sensitivity to daratumumab.

12 d to evaluate CD38-specificity of (89)Zr-DFO-daratumumab.

13 treated with 185 kBq or 277.5 kBq of (212)Pb-daratumumab.

14 ved 74 MBq (2 mCi) of intravenous (89)Zr-DFO-daratumumab.

15 es showed a specific tumoral accumulation of daratumumab.

16 y of subcutaneous daratumumab to intravenous daratumumab.

17 ent dosing was per the approved schedule for daratumumab.

18 analysis included 148 patients who received daratumumab 16 mg/kg (42 patients in GEN501 part 2; 106

19 Patients received daratumumab 16 mg/kg at the recommended dosing schedule,

20 e reported for the 106 patients who received daratumumab 16 mg/kg in parts 1 and 2.

21 In this pooled data set, daratumumab 16 mg/kg monotherapy demonstrated rapid, dee

22 In this analysis, daratumumab 16 mg/kg monotherapy showed durable response

23 2 of GEN501, patients were given intravenous daratumumab 16 mg/kg once per week for 8 weeks, twice pe

24 t 2 of SIRIUS, patients received intravenous daratumumab 16 mg/kg once per week for 8 weeks, twice pe

25 Daratumumab 16 mg/kg was administered by IV infusion onc

26 pooled analysis of 148 patients treated with daratumumab 16 mg/kg.

27 alone (control group) or in combination with daratumumab (16 mg per kilogram of body weight) (daratum

28 r 28-day cycles of Dara-KRd, each comprising daratumumab (16 mg/kg intravenously on days 1, 8, 15, an

29 in the D-VMP group also received intravenous daratumumab (16 mg/kg of bodyweight, once weekly during

30 n day 1 of each 21-day cycle) or intravenous daratumumab (16 mg/kg once a week in cycles 1-3, every 3

31 4), and 20 mg after cycle 4; and intravenous daratumumab, 16 mg/kg (days 1, 8, 15, and 22 [cycles 1-2

32 Daratumumab (1800 mg subcutaneously or 16 mg/kg intraven

33 ocated in a 1:1 ratio to receive intravenous daratumumab 8 mg/kg or 16 mg/kg in part 1 stage 1 of the

34 Daratumumab (8 mg/kg) was administered intravenously on

35 e report the use of CD38 monoclonal antibody daratumumab (9-mo course) in a kidney allograft recipien

36 previously treated AL patients who received daratumumab, a CD38-directed monoclonal antibody approve

37 We studied daratumumab, a CD38-targeting, human IgG1kappa monoclona

38 Daratumumab, a human CD38 immunoglobulin G1 kappa (IgG1k

39 Daratumumab, a human IgGkappa monoclonal antibody that t

40 Daratumumab, a human monoclonal antibody targeting CD38,

41 Daratumumab, a human monoclonal antibody that targets CD

42 Daratumumab, a monoclonal antibody targeting CD38, has b

43 Daratumumab, a monoclonal CD38 antibody, is approved in

44 We assessed daratumumab, a novel CD38-targeted monoclonal antibody,

45 Patients received subcutaneous daratumumab according to the approved IV monotherapy dos

46 mbination of TAK-981 with anti-CD38 antibody daratumumab also resulted in enhanced antitumor activity

47 Daratumumab, an anti-CD38 monoclonal antibody, has been

48 e, 30 patients received 8 mg per kilogram of daratumumab and 42 received 16 mg per kilogram, administ

49 therapy, of whom 24.7% versus 33.9% received daratumumab and 71.8% versus 76.9% received PIs (next-li

50 8 on tumor cells on a different epitope than daratumumab and a detuned scFv domain affinity binding t

51 possible additional mechanisms of action for daratumumab and deserves further exploration.

52 ab'(OBN)-MORF1), whereas Fab' fragments from Daratumumab and Isatuximab (Fab'(DARA)-MORF1 and Fab'(IS

53 antitumor efficacy and better survival than daratumumab and isatuximab against EL4 thymoma or VK*MYC

54 ave shown enhanced therapeutic efficacy when daratumumab and isatuximab are combined with other agent

55 ar cytotoxicity of the commercial antibodies daratumumab and isatuximab.

56 rs; four of them were also desensitized with daratumumab and plerixafor (anti-CXCR4).

57 ill review data on the use of elotuzumab and daratumumab and provide a foundation for their use in cu

58 luated a mix-and-deliver (MD) formulation of daratumumab and rHuPH20 (DARA-MD) administered by subcut

59 onsistent with the known safety profiles for daratumumab and VRd.

60 ib, carfilzomib, lenalidomide, pomalidomide, daratumumab, and an alkylating agent and had disease ref

61 Furthermore, daratumumab, and probably also other CD38-targeting anti

62 , we treated sensitized rhesus macaques with daratumumab (anti-CD38 mAb).

63 ated the potential of alpha-RIT with (212)Pb-Daratumumab (anti-CD38), in both in vitro and in vivo mo

64 ated the potential of alpha-RIT with (212)Pb-daratumumab (anti-hCD38), in both in vitro and in vivo m

65 This supports investigation of daratumumab as a potential therapeutic strategy; however

66 , the dose-escalation phase, we administered daratumumab at doses of 0.005 to 24 mg per kilogram of b

67 Part 2 (dose expansion) evaluated daratumumab at the recommended phase 2 dose (RP2D) plus

68 based on lenalidomide/bortezomib resistance, daratumumab availability, and cost.

69 s, daratumumab is clearly a breakthrough and daratumumab-based combinations might become the preferre

70 Daratumumab-based regimens achieve deep hematologic and

71 However, daratumumab-based therapy improved rates of MRD negativi

72 Frontline daratumumab-based triplet and quadruplet standard-of-car

73 Daratumumab binds a unique CD38 epitope and showed stron

74 Daratumumab bioconjugates are being evaluated for image-

75 The daratumumab+bortezomib combination is emerging as a nove

76 in, bortezomib, and dexamethasone (n=243) or daratumumab, bortezomib, and dexamethasone (n=251).

77 gression-free survival benefit compared with daratumumab, bortezomib, and dexamethasone in relapsed o

78 ntly improved progression-free survival with daratumumab, bortezomib, thalidomide, and dexamethasone

79 Above all, the daratumumab-bortezomib combination is a new standard-of-

80 r daratumumab/dexamethasone (DD, n = 106) or daratumumab/bortezomib/dexamethasone (DVD, n = 62).

81 Patients received 1800 mg of subcutaneous daratumumab co-formulated with 2000 U/mL recombinant hum

82 An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and

83 after three days of incubation with (212)Pb-Daratumumab compared to (212)Pb-Isotypic Control or cold

84 CI 0.39-0.57)] was less likely to occur with daratumumab compared to control.

85 bserved after 3 d of incubation with (212)Pb-daratumumab, compared with (212)Pb-isotypic control or c

86 Confocal microscopy with daratumumab-Cy5 demonstrated specific cell binding.

87 ANDROMEDA study (NCT03201965) is evaluating daratumumab-CyBorD vs CyBorD in newly diagnosed AL amylo

88 Daratumumab-CyBorD was well tolerated, with no new safet

89 The addition of daratumumab (D) to RVd (D-RVd) in transplant-eligible ND

90 VTd alone (VTd group) or in combination with daratumumab (D-VTd group).

91 Patients received subcutaneous daratumumab (DARA SC) weekly in cycles 1 to 2, every 2 w

92 Anti-CD38 monoclonal antibodies like Daratumumab (Dara) are effective in multiple myeloma (MM

93 Daratumumab (DARA), a human monoclonal antibody targetin

94 In this study, we show that daratumumab (DARA), a therapeutic human CD38 mAb with a

95 Daratumumab demonstrated an acceptable safety profile an

96 B-NHL, the targeting with anti-CD38 antibody daratumumab demonstrated highly improved anti-lymphoma e

97 [(89)Zr]Zr-DFO- and Cy5-daratumumab demonstrated superb binding to CD38(+) human

98 8 patients with advanced AL receiving either daratumumab/dexamethasone (DD, n = 106) or daratumumab/b

99 g) was reproducibly obtained with [(89)Zr]Zr-daratumumab-DFO.

100 levels on MM cells increased again following daratumumab discontinuation.

101 Because daratumumab does not bind the murine CD38, biodistributi

102 As Daratumumab does not bind the murine CD38, biodistributi

103 Of these, 10 patients received the first daratumumab dose as a single infusion (16 mg/kg, day 1 c

104 luded all patients who received at least one daratumumab dose.

105 d all patients who received all eight weekly daratumumab doses in cycles 1 and 2 and provided a pre-d

106 Part 1 (dose escalation) evaluated 4 daratumumab doses plus lenalidomide (25 mg/day orally on

107 Conclusion: These results showed (212)Pb-Daratumumab efficacy on xenografted mice with significan

108 Patients received 6 28-day cycles of IV daratumumab, every week for cycles 1 and 2 and every 2 w

109 Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a

110 Intravenous daratumumab for treatment of patients with multiple myel

111 e chelator deferoxamine (DFO), or (89)Zr-DFO-daratumumab, for immunologic PET imaging of multiple mye

112 ntribute to the approval of the subcutaneous daratumumab formulation by regulatory bodies.

113 lopment of several CD38 antibodies including daratumumab (fully human), isatuximab (chimeric), and MO

114 nt-related adverse event in the subcutaneous daratumumab group (febrile neutropenia) and four in the

115 s were enrolled and randomly assigned to the daratumumab group (n=368) or the control group (n=369).

116 patients (97 of 368 patients [26.4%] in the daratumumab group and 143 of 369 patients [38.8%] in the

117 enrolled patients, 194 were assigned to the daratumumab group and 196 to the active-monitoring group

118 complete response or better was 47.6% in the daratumumab group and 24.9% in the control group (P<0.00

119 A total of 15 patients (7.7%) in the daratumumab group and 26 patients (13.3%) in the active-

120 nfidence interval [CI], 65.0 to 75.4) in the daratumumab group and 55.6% (95% CI, 49.5 to 61.3) in th

121 grade 3 or 4 adverse events reported in the daratumumab group and the control group were thrombocyto

122 ression-free survival was not reached in the daratumumab group and was 7.2 months in the control grou

123 e rate of overall response was higher in the daratumumab group than in the control group (82.9% vs. 6

124 ree survival was significantly higher in the daratumumab group than in the control group; the 12-mont

125 f progression-free survival was 60.7% in the daratumumab group versus 26.9% in the control group.

126 not reached (95% CI 54.8-not reached) in the daratumumab group versus 34.4 months (29.6-39.2) in the

127 grade 3 or 4 were neutropenia (50.0% in the daratumumab group vs. 35.3% in the control group), anemi

128 patients to 102 [76%] of 134 patients in the daratumumab group) of the EORTC QLQ-C30 and of the disea

129 tumumab plus lenalidomide and dexamethasone (daratumumab group) or lenalidomide and dexamethasone alo

130 patients to 92 [69%] of 134 patients in the daratumumab group), and physical functioning domains (13

131 patients to 156 [65%] of 240 patients in the daratumumab group), role functioning (103 [53%] of 196 p

132 tumumab (16 mg per kilogram of body weight) (daratumumab group).

133 patients to 164 [74%] of 221 patients in the daratumumab group).

134 scontinuation in 5.7% of the patients in the daratumumab group, and no new safety concerns were ident

135 A total of 24.2% of the patients in the daratumumab group, as compared with 7.3% of the patients

136 eutropenia and pneumonia was observed in the daratumumab group.

137 ere reported in 45.3% of the patients in the daratumumab group; these reactions were mostly grade 1 o

138 In contrast, the alpha-emitter 225Ac-DOTA-daratumumab had a dose-dependent effect, in which 0.925,

139 ith PGNMID who received at least one dose of daratumumab had a partial response, and four had a compl

140 The animals treated with daratumumab had significantly reduced donor-specific ant

141 Daratumumab has shown clinical benefit in multiple myelo

142 Daratumumab has shown promising first results in systemi

143 Carfilzomib in combination with daratumumab has shown substantial efficacy with tolerabl

144 Daratumumab has single agent activity and a limited toxi

145 myeloma, and trials for both elotuzumab and daratumumab have demonstrated significant activity when

146 ACI panobinostat, and 2 mAbs, elotuzumab and daratumumab, have been approved, incorporated into clini

147 r radioimmunotherapy using radiolabeled DOTA-daratumumab in a preclinical model of disseminated multi

148 centrations and responses consistent with IV daratumumab in a similar patient population.

149 Further studies of daratumumab in combination regimens are warranted.

150 or relapsed and refractory multiple myeloma, daratumumab in combination with bortezomib and dexametha

151 -free survival was significantly longer with daratumumab in combination with bortezomib, melphalan, a

152 and prolonged progression-free survival with daratumumab in combination with bortezomib, thalidomide,

153 study evaluated subcutaneously administered daratumumab in combination with the recombinant human hy

154 Based on outcomes of daratumumab in multiple myeloma (MM), the phase 3 ANDROM

155 ts Single-agent activity was seen when using daratumumab in refractory myeloma, and trials for both e

156 daratumumab was non-inferior to intravenous daratumumab in terms of efficacy and pharmacokinetics an

157 We also treated two patients with daratumumab in the context of transplant.

158 Daratumumab in Treatment of PGNMID and C3 GN, NCT0309511

159 In parallel, daratumumab induced robust increases in helper and cytot

160 In PB and BM, daratumumab induced significant increases in CD8(+):CD4(

161 nd circulating MM cells, following the first daratumumab infusion.

162 acokinetics, immunogenicity, and accelerated daratumumab infusions were studied.

163 an survival of 55 d for 277.5 kBq of (212)Pb-daratumumab instead of 11 d for phosphate-buffered salin

164 survival of 55 days for 277.5 kBq of (212)Pb-Daratumumab instead of 11 for PBS control groups.

165 uration on reagent red blood cells mitigates daratumumab interference with transfusion laboratory ser

166 However, daratumumab is a costly treatment and is administered in

167 Daratumumab is a highly effective agent that produced ra

168 Daratumumab is a human monoclonal antibody targeting CD3

169 Daratumumab is a monoclonal antibody that targets CD38,

170 Daratumumab is a U.S. Food and Drug Administration-appro

171 Currently, daratumumab is administered IV.

172 ly treated with immune-modulatory drugs, but daratumumab is also an effective option.

173 Among these agents, daratumumab is clearly a breakthrough and daratumumab-ba

174 Daratumumab is increasingly used in first-line, and soon

175 changing the paradigm of MM management, and daratumumab is the first-in-class human monoclonal antib

176 Subcutaneous daratumumab is thought to be easier to administer and to

177 The anti-CD38 monoclonal antibody daratumumab is well tolerated and has high single agent

178 In summary, daratumumab is well tolerated in patients with relapsed

179 A monoclonal anti-CD38 antibody (daratumumab) is effective in treating multiple myeloma.

180 rious therapeutic CD38 antibodies, including daratumumab, isatuximab, and MOR202.

181 t patients with newly diagnosed MM receiving daratumumab-ixazomib-dexamethasone, even after adjusting

182 igned 2:1 to carfilzomib, dexamethasone, and daratumumab (KdD) or carfilzomib and dexamethasone (Kd).

183 cation of an antibody composed of the native daratumumab labeled with the positron-emitting radionucl

184 Daratumumab led to persistent CD138+ cell depletion in t

185 e basis of this analysis, the combination of daratumumab, lenalidomide, and dexamethasone seems to be

186 Results The combination of daratumumab, lenalidomide, and dexamethasone was identif

187 and June 18, 2018, 886 were re-randomised to daratumumab maintenance (n=442) or observation (n=444).

188 in the VTd group) were randomly assigned to daratumumab maintenance (n=442) or observation only (n=4

189 D-VTd followed by daratumumab maintenance consistently produced the highes

190 Daratumumab maintenance every 8 weeks for 2 years signif

191 Daratumumab maintenance improved overall MRD-negativity

192 Furthermore, daratumumab maintenance provided PFS benefit vs observat

193 In CASSIOPEIA part 2, daratumumab maintenance significantly improved progressi

194 as an important regulator of sensitivity to Daratumumab-mediated antibody-dependent cellular cytotox

195 This resulted in significant enhancement of daratumumab-mediated complement-dependent cytotoxicity.

196 showed that IFNgamma significantly increased daratumumab-mediated cytotoxicity, as measured both by (

197 her, these studies show a novel mechanism of daratumumab-mediated killing and a possible new therapeu

198 To evaluate the in vivo efficacy of (212)Pb-daratumumab, mice were engrafted subcutaneously with 5 x

199 To evaluate in vivo efficacy of (212)Pb-Daratumumab, mice were engrafted subcutaneously with 5.1

200 In a cohort of 102 patients treated with daratumumab monotherapy (16 mg/kg), we found that pretre

201 This prospective phase 2 trial of daratumumab monotherapy for the treatment of AL amyloido

202 Daratumumab monotherapy had a favorable safety profile a

203 f a prospective multicenter phase 2 study of daratumumab monotherapy in AL (NCT02816476).

204 The efficacy and favorable safety profile of daratumumab monotherapy in multiple myeloma (MM) was pre

205 t frequent adverse events during maintenance daratumumab monotherapy in patients in the D-VMP group w

206 Daratumumab monotherapy is associated with deep and rapi

207 Daratumumab monotherapy showed encouraging efficacy in h

208 ents with relapsed/refractory myeloma from 2 daratumumab monotherapy studies were analyzed before and

209 sk smoldering multiple myeloma, subcutaneous daratumumab monotherapy was associated with a significan

210 observed with lenalidomide/dexamethasone or daratumumab monotherapy.

211 ts eventually develop progressive disease to daratumumab monotherapy.

212 Carfilzomib- and daratumumab-naive patients (n = 85) received carfilzomib

213 yaluronidase PH20 or 16 mg/kg of intravenous daratumumab once weekly (cycles 1-2), every 2 weeks (cyc

214 ent with an intravenous injection of (212)Pb-daratumumab or control solution.

215 ent with an intravenous injection of (212)Pb-Daratumumab or control solutions.

216 rtial response (PR) after 2 cycles continued daratumumab, otherwise lenalidomide or bortezomib was ad

217 e evaluated [(89)Zr]Zr-desferrioxamine (DFO)-daratumumab PET/CT imaging in MM tumor models.

218 [(89)Zr]Zr-DFO-daratumumab PET/CT small-animal imaging was performed in

219 [(89)Zr]Zr-DFO-daratumumab/PET demonstrated specificity and sensitivity

220 were efficiently imaged with [(89)Zr]Zr-DFO-daratumumab/PET.

221 oietic stem-cell transplantation (HSCT) with daratumumab plus bortezomib, thalidomide, and dexamethas

222 This phase 1b study evaluated daratumumab plus carfilzomib and dexamethasone (D-Kd) in

223 ineligible NDMM, triplet therapy with either daratumumab plus lenalidomide and dexamethasone (D-Rd) o

224 ologous stem-cell transplantation to receive daratumumab plus lenalidomide and dexamethasone (daratum

225 Daratumumab plus lenalidomide and dexamethasone increase

226 significantly lower among those who received daratumumab plus lenalidomide and dexamethasone than amo

227 This phase 1/2 study investigated daratumumab plus lenalidomide/dexamethasone in refractor

228 Daratumumab plus lenalidomide/dexamethasone resulted in

229 increased neutropenia, the safety profile of daratumumab plus pom-dex was consistent with that of the

230 The safety profile of daratumumab plus pom-dex was similar to that of pom-dex

231 Daratumumab plus pomalidomide and dexamethasone (pom-dex

232 3 [47%] women) were randomly assigned to the daratumumab plus pomalidomide and dexamethasone group (n

233 patients were randomly assigned: 151 to the daratumumab plus pomalidomide and dexamethasone group an

234 ollow-up of 16.9 months (IQR 14.4-20.6), the daratumumab plus pomalidomide and dexamethasone group sh

235 al was 34.4 months (95% CI 23.7-40.3) in the daratumumab plus pomalidomide and dexamethasone group ve

236 reported here continue to support the use of daratumumab plus pomalidomide and dexamethasone in patie

237 to randomly assign patients (1:1) to receive daratumumab plus pomalidomide and dexamethasone or pomal

238 ith relapsed or refractory multiple myeloma, daratumumab plus pomalidomide and dexamethasone reduced

239 first study showing the clinical benefit of daratumumab plus standard of care in transplant-eligible

240 triple-class-refractory disease, and 95% had daratumumab-refractory disease.

241 in vitro genome-wide CRISPR screens probing Daratumumab resistance, KDM6A as an important regulator

242 sion on MM cells from patients who developed daratumumab resistance, to approximately pretreatment va

243 t express CD38, which prompted evaluation of daratumumab's effects on CD38-positive immune subpopulat

244 Daratumumab salvage therapy produced good results and re

245 t role for CD38 and CIP expression levels in daratumumab sensitivity and suggest that therapeutic com

246 evaluated for immunosuppressive activity and daratumumab sensitivity in the myeloma setting.

247 Daratumumab showed encouraging efficacy as monotherapy i

248 t 7 d after administration of [(89)Zr]Zr-DFO-daratumumab showed prominent tumor uptake (27.7 +/- 7.6

249 , we found that treatment with IFNgamma plus daratumumab significantly attenuated tumor growth.

250 ough treatment of multiple myeloma (MM) with daratumumab significantly extends the patient's lifespan

251 Targeting CD38 with daratumumab significantly reduced anti-HLA antibodies an

252 that of pom-dex alone, with the exception of daratumumab-specific infusion-related reactions (50%) an

253 ed using randomly permuted blocks to receive daratumumab subcutaneously (subcutaneous group) or intra

254 treatment for MM is the monoclonal antibody Daratumumab, targeting the CD38 receptor, which is highl

255 Daratumumab targets CD38-expressing myeloma cells throug

256 We describe the use of daratumumab that induced substantial clinical responses

257 ponse study with the beta-emitter 177Lu-DOTA-daratumumab, the lowest tested dose, 1.85 MBq, extended

258 ated with patients who were able to continue daratumumab therapy alone.

259 Conclusion: These results showed (212)Pb-daratumumab to have efficacy in xenografted mice, with s

260 e tested the non-inferiority of subcutaneous daratumumab to intravenous daratumumab.

261 Addition of daratumumab to lenalidomide, bortezomib, and dexamethaso

262 Addition of daratumumab to RVd improved the depth of response and pr

263 -VTd versus VTd, and support the addition of daratumumab to standard regimens in patients with newly

264 Here, we examine the addition of daratumumab to the second-generation proteasome inhibito

265 We evaluated whether the addition of daratumumab to VTd before and after autologous stem-cell

266 than CD38-negative Tregs and were reduced in daratumumab-treated patients.

267 -related reactions that were associated with daratumumab treatment were reported in 45.3% of the pati

268 e inhibitor, one immunomodulatory agent, and daratumumab (triple-class refractory).

269 Delaying daratumumab until subsequent lines of therapy may be a r

270 No toxicity was observed with (212)Pb-daratumumab up to 370 kBq because of lack of cross-react

271 No toxicity was observed with (212)Pb-Daratumumab up to 370 kBq due to the lack of cross-react

272 (89)Zr-DFO-daratumumab uptake was visualized at PET in sites of oss

273 reached (95% CI not evaluable [NE]-NE) with daratumumab versus 46.7 months (40.0-NE) with observatio

274 nd safety of carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone in pati

275 of induction/consolidation treatment (D-VTd/daratumumab vs D-VTd/observation, 10-5 [77.3% vs 70.7%]

276 .3% vs 70.7%] and 10-6 [60.7% vs 52.0%]; VTd/daratumumab vs VTd/observation, 10-5 [70.9% vs 51.2%] an

277 (hazard ratio for progression or death with daratumumab vs. control, 0.39; 95% confidence interval,

278 The overall hematologic response rate to daratumumab was 76%, including CR in 36% and very good p

279 Daratumumab was administered at 16 mg/kg weekly for 8 we

280 First-line daratumumab was associated with an improvement of 0.52 Q

281 Daratumumab was conjugated to Cyanine5 (Cy5) dye for cel

282 Daratumumab was conjugated to DFO-p-benzyl-isothiocyanat

283 q/mL) of (212)Pb-isotypic control or (212)Pb-daratumumab was evaluated.

284 q/ml) of (212)Pb-isotypic control or (212)Pb-Daratumumab was evaluated.

285 Subcutaneous daratumumab was non-inferior to intravenous daratumumab

286 tro and in vivo evaluation of [(89)Zr]Zr-DFO-daratumumab was performed using CD38(+) human myeloma MM

287 In humans, (89)Zr-DFO-daratumumab was safe and demonstrated acceptable dosimet

288 Materials and Methods (89)Zr-DFO-daratumumab was synthesized by conjugating (89)Zr to dar

289 Results (89)Zr-DFO-daratumumab was synthesized with radiochemical purity gr

290 Daratumumab was well tolerated, with no unexpected adver

291 Daratumumab was well tolerated; fatigue (42 [40%] patien

292 otherapy with anti-CD38 monoclonal antibody (daratumumab) was proposed with a clinical and biological

293 l patients who received at least one dose of daratumumab were included in the analysis.

294 myeloma (MM) include the anti-CD38 antibody daratumumab, which, in addition to its inherent cytotoxi

295 on, R140G, conferred selective resistance to daratumumab, while retaining sensitivity to isatuximab.

296 ine, and soon patients that relapse while on daratumumab will become a common challenge.

297 mab was synthesized by conjugating (89)Zr to daratumumab with DFO.

298 Daratumumab with RVd induction and consolidation improve

299 Combining daratumumab with VRd produced deeper and more durable MR

300 sought to determine whether the addition of daratumumab would significantly reduce the risk of disea